HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Rating of “Hold” by Analysts

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) have been given an average rating of “Hold” by the six analysts that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $14.8667.

HCM has been the subject of several research reports. Weiss Ratings lowered HUTCHMED from a “hold (c-)” rating to a “sell (d)” rating in a research note on Friday. Morgan Stanley set a $13.60 target price on HUTCHMED in a research report on Thursday, May 28th. Bank of America decreased their price target on HUTCHMED from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. Finally, The Goldman Sachs Group dropped their price target on HUTCHMED from $16.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, July 23rd.

HUTCHMED Stock Up 3.8%

HCM stock opened at $11.55 on Thursday. HUTCHMED has a 12 month low of $9.77 and a 12 month high of $18.30. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.64 and a quick ratio of 5.50. The firm has a 50 day simple moving average of $10.99 and a 200 day simple moving average of $13.18.

HUTCHMED (NASDAQ:HCM) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.14 by ($0.09). The business had revenue of $139.14 million for the quarter, compared to analysts’ expectations of $304.16 million. On average, research analysts anticipate that HUTCHMED will post 0.28 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in HCM. State Street Corp raised its holdings in shares of HUTCHMED by 1.2% during the fourth quarter. State Street Corp now owns 321,305 shares of the company’s stock valued at $4,283,000 after acquiring an additional 3,801 shares during the period. M&G PLC boosted its stake in HUTCHMED by 26.7% in the 4th quarter. M&G PLC now owns 259,033 shares of the company’s stock worth $3,367,000 after purchasing an additional 54,601 shares during the period. Amundi boosted its stake in HUTCHMED by 4.0% in the 1st quarter. Amundi now owns 232,246 shares of the company’s stock worth $3,474,000 after purchasing an additional 8,916 shares during the period. Jane Street Group LLC grew its position in HUTCHMED by 128.0% during the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock worth $3,343,000 after purchasing an additional 124,771 shares in the last quarter. Finally, UBS Group AG raised its stake in HUTCHMED by 112.8% during the 3rd quarter. UBS Group AG now owns 137,000 shares of the company’s stock valued at $2,158,000 after purchasing an additional 72,614 shares during the period. 8.82% of the stock is currently owned by institutional investors and hedge funds.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.